Endo Pharmaceuticals was founded in 1997 as a leveraged buyout discharge from DuPont Merck. In 1999, he must decide whether to do an IPO or a merger with a smaller company. "Hide
by Richard G. Hamermesh, Brian J. Delacey Source: Harvard Business School 21 pages. Publication Date: January 30, 2006. Prod. #: 806064-PDF-ENG
Related Case Solutions & Analyses:
Plans versus Politics: New Orleans after Katrina
House of Tata: Acquiring a Global Footprint
Apple Computer–John Sculley Chairman & CEO–Presentation to ISMP Participants July 6 1992 Video
Paperless Healthcare: Progress and Challenges of an IT-Enabled Healthcare System
SECURITY ANALYSIS: WARREN BUFFET’S 5 BILLION INVESTMENTS
THE WALT DISNEY COMPANY AND PIXAR INCTO ACQUIRE OR NOT TO ACQUIRE
AQUALISA QUARTZ: SIMPLY A BETTER SHOWER
A. P. Moller – Maersk Group: Evaluating Strategic Talent Management Initiatives
General Electric after GE Capital
AutoZone
